Phoenix Nest, Inc. is a biotechnology company developing treatments and cures for Sanfilippo Syndrome IIIC and IIID. Sanfilippo syndrome (mucopolysaccharidosis type III; MPS III) is a devastating neurodegenerative lysosomal storage disorder of childhood. As of 2014, the company had several products all of which were in preclinical stages of development. These therapies include enzyme replacement therapy (for IIID), Chaperone therapy (IIIC), and Gene therapy (IIIC). The firm actively collaborate with academic researchers to fund and commercialize their technologies. Phoenix Nest, Inc. also licenses assets from companies and universities that may have utility for Sanfilippo Syndrome.
